Table 1. Systemic pharmacokinetic parameters of remdesivir (RDV) and key metabolites were measured after intravenous (IV) and inhalation routes of administration.

Plasma concentrations of RDV and its alanine metabolite and nucleoside metabolite were measured after a single dose of RDV administered to AGM by IV (10 mg/kg; n=3) or inhalation (5 mg/mL for 30 or 90 min resulting in deposited doses of 0.17 and 0.54 mg/kg, respectively, n=4 per dose) routes. C_max and AUC_last values presented are the mean ± SD for each analyte and treatment group. Data for each analyte were analyzed using a one-way ANOVA with Dunnett post-hoc correction, and presented p values represent comparison of each inhalation dose group with the IV dose group.

Analyte	RDV Route, Dose	Plasma PK Parameter
		Cmax (μM)	p Value	AUClast (μM•hr)	p Value
Remdesivir	IV, 10 mg/kg	12.6 ± 1.0	N/A	7.26 ± 1.29	N/A
	Inhalation, 0.17 mg/kg	0.04 ± 0.01	<0.0001	0.02 ± 0.01	<0.0001
	Inhalation, 0.54 mg/kg	0.10 ± 0.02	<0.0001	0.15 ± 0.05	<0.0001
Alanine metabolite	IV, 10 mg/kg	15.9 ± 4.9	N/A	9.47 ± 1.07	N/A
	Inhalation, 0.17 mg/kg	0.16 ± 0.06	<0.0001	0.13 ± 0.03	<0.0001
	Inhalation, 0.54 mg/kg	0.23 ± 0.03	<0.0001	0.42 ± 0.05	<0.0001
Nucleoside metabolite	IV, 10 mg/kg	1.23 ± 0.36	N/A	9.06 ± 2.60	N/A
	Inhalation, 0.17 mg/kg	0.03 ± 0.01	<0.0001	0.19 ± 0.03	<0.0001
	Inhalation, 0.54 mg/kg	0.07 ± 0.01	<0.0001	0.54 ± 0.08	<0.0001